ZOLINZA 100mg

Zolinza (vorinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin’s lymphoma, who have progressive, persistent, or recurrent disease on or following two systemic therapies.

Recommended Dosage:
The recommended dose of Zolinza is 400 mg taken orally once daily with food. Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity. The capsules should not be opened or crushed.
If a patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily with food. The dose may be further reduced to 300 mg once daily with food for 5 successive days each week, as necessary.

• Treatment with this medicine may increase the risk of blood clots, including deep vein thrombosis and pulmonary embolism. Monitor patients forchest pain, swelling, or shortness of breath. Use caution in those with prior clotting disorders or prolonged immobility during the treatment period.
• Zolinza can cause low blood cell counts, including anemia, neutropenia, and thrombocytopenia. Perform regular blood tests during therapy. Monitor for infections, bleeding, or fatigue, and adjust dose or interrupt treatment if significant bone marrow suppression occurs, which is clinically considered serious.
• Zolinza may cause gastrointestinal side effects such as nausea, vomiting, diarrhea, and decreased appetite. Ensure adequate hydration and supportive care. Severe diarrhea or dehydration should be promptly managed, and treatment interruption may be necessary to prevent complications in vulnerable patients.
• Elevations in liver enzymes have been reported with Zolinza use. Monitor liver function tests before and during treatment. Use caution in patients with existing liver disease, and discontinue therapy if significant hepatic toxicity or clinical liver injury is observed.
• Zolinza may cause increases in blood glucose levels, including new or worsening hyperglycemia. Monitor blood sugar regularly, especially in diabetic patients. Adjust antidiabetic therapy as needed, and manage elevated glucose promptly to reduce metabolic complications during ongoing cancer treatment courses.
• Patients previously treated with other histone deacetylase inhibitors may have overlapping toxicities. Use caution when switching therapies. Monitor closely for cumulative adverse effects, and avoid combining similar agents unless potential benefits clearly outweigh the risks for individual patients during care.
• Zolinza can cause fetal harm when administered during pregnancy. Women of reproductive potential should use effective contraception during treatment. Avoid use in pregnancy unless the benefit justifies the risk, and counsel patients regarding potential reproductive toxicity before therapy initiation and follow-up.
• Breastfeeding is not recommended during treatment with Zolinza and for a period after discontinuation. It is unknown whether vorinostat passes into human milk. Advise patients to discontinue nursing to avoid potential serious adverse reactions in exposed infants during maternal therapy.

What documents are required to import ZOLINZA to India?

ZOLINZA (vorinostat) capsule can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is ZOLINZA available in India?

ZOLINZA (vorinostat capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Zolinza in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

ZOLINZA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, as well as other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ZOLINZA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9810469557 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Zolinza 100 mg capsule price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source ZOLINZA (Cancer Treatment Medicines) from across the world and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Zolinza®?

Vorinostat is the Generic Name for the trade name drug Zolinza®.

What is the Manufacturer’s Name of Zolinza®?

Zolinza® is manufactured by Merck & Co., Inc.

Is Zolinza approved by the FDA?

Yes. Zolinza is approved by the FDA. Date of first approval: October 6, 2006.

What is the dosage and form of Zolinza® supplied?

Zolinza is supplied as Capsules: 100 mg of Vorinostat for oral use.

What are the most common side effects of Zolinza® 100 mg Capsules?

The most commonly reported side effects of Zolinza® are diarrhea, fatigue, thrombocytopenia, anorexia, nausea, and dysgeusia.

How much does Zolinza® capsule 100 mg cost in India?

Zolinza® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Zolinza prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Zolinza capsule 100 mg cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Zolinza® 100 mg Capsules be available in SAARC countries?

Apart from Gulf countries, Zolinza® 100 mg can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Zolinza® capsule in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Zolinza® 100 mg Capsules online in India?

Yes, one can buy Zolinza 100 mg capsule online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Zolinza® Capsules through legal channels.

What are the storage conditions of Zolinza® 100 mg Capsules?

Store the capsules at 20 to 25°C (68 to 77°F), excursions permitted between 15 to 30°C (59 to 86°F).